Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans)

Hashemi, Leila; Hsiung, Jui-Ting; Arif, Yousif; Soohoo, Melissa; Jackson, Nicholas; Gosmanova, Elvira O.; Budoff, Matthew J.; Kövesdy, Csaba P.; Kalantar‐Zadeh, Kamyar; Streja, Elani

doi:10.1016/j.amjcard.2022.01.034

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional pathogenic features of nephropathy in the obese include increased GFR and renal plasma flow, increased filtration fraction and Na + tubular reabsorption; this would lead to increased fluid shear stress on podocytes, phenomena of maladaptive renal hypertrophy, detachment of podocytes and, finally, global glomerulosclerosis [98] . Importantly, innovative super-resolution ultrasound Imaging techniques identify structural alterations in the renal vasculature [99] .…”

Section: Obesity-related Nephropathymentioning

confidence: 99%

Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review

Lonardo

2024

Metab Target Organ Damage

View full text Add to dashboard Cite

Chronic kidney disease (CKD) and nonalcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) account for substantial financial burden worldwide. These alarming features call for enhanced efforts to prevent and manage the development and progression of CKD. Accumulating evidence supporting a causal role of NAFLD/MAFLD/MASLD-in CKD opens new horizons to achieve this aim. Recent epidemiological studies and meta-analyses exploring the association of NAFLD/MAFLD/MASLD with CKD and the characteristics of NAFLD/MAFLD/MASLD associated with the odds of incident CKD are discussed. The involved pathomechanisms, including the common soil hypothesis, genetics, gut dysbiosis, and portal hypertension, are examined in detail. Finally, lifestyle changes (diet and physical exercise), direct manipulation of gut microbiota, and drug approaches involving statins, renin-angiotensin-aldosterone system inhibitors, GLP-1 Receptor Agonists, Sodium-glucose cotransporter-2, pemafibrate, and vonafexor are examined within the context of prevention and management of CKD among those with NAFLD/MAFLD/MASLD. The evolving NAFLD/MAFLD/MASLD nomenclature may generate confusion among practicing clinicians and investigators. However, comparative studies investigating the pros and contra of different nomenclatures may identify the most useful definitions among NAFLD/MAFLD/MASLD and strategies to identify, prevent, and halt the onset and progression of CKD.

show abstract

Section: Obesity-related Nephropathymentioning

confidence: 99%

Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review

Lonardo

2024

Metab Target Organ Damage

View full text Add to dashboard Cite

show abstract

“…Diabetic kidney disease (DKD) is one of the most common complications of diabetes, and by 2040, more than 600 million people worldwide are expected to have diabetes, of whom 30–40% will develop DKD. It has become the major cause of chronic kidney disease in many developed and developing countries [ 1 , 2 ]. DKD is the most common cause of end-stage renal disease (ESRD) worldwide, chronic kidney disease is the dominant contributor to excess mortality in patients with type 2 diabetes [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease

et al. 2022

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is one of the most common complications of diabetes, and its prevalence is still growing rapidly. However, the efficient therapies for this kidney disease are still limited. The pathogenesis of DKD involves glucotoxicity, lipotoxicity, inflammation, oxidative stress, and renal fibrosis. Glucotoxicity and lipotoxicity can cause oxidative stress, which can lead to inflammation and aggravate renal fibrosis. In this review, we have focused on in vitro and in vivo experiments to investigate the mechanistic pathways by which natural compounds exert their effects against the progression of DKD. The accumulated and collected data revealed that some natural compounds could regulate inflammation, oxidative stress, renal fibrosis, and activate autophagy, thereby protecting the kidney. The main pathways targeted by these reviewed compounds include the Nrf2 signaling pathway, NF-κB signaling pathway, TGF-β signaling pathway, NLRP3 inflammasome, autophagy, glycolipid metabolism and ER stress. This review presented an updated overview of the potential benefits of these natural compounds for the prevention and treatment of DKD progression, aimed to provide new potential therapeutic lead compounds and references for the innovative drug development and clinical treatment of DKD.

show abstract

Post-treatment level of LDL cholesterol and all-cause mortality in patients with atherosclerotic cardiovascular disease: evidence from real-world setting

Luo,

Lin,

Zhang

et al. 2023

European Journal of Preventive Cardiology

View full text Add to dashboard Cite

Aims This study aimed to evaluate the safety of currently recommended target of LDL-C control on mortality in patients with atherosclerotic cardiovascular disease (ASCVD). Methods Using deidentified electronic health record data, we conducted a multicenter retrospective cohort study involving individuals with documented ASCVD who had received statin treatment for at least 3 months across China. The primary outcomes assessed encompassed all-cause mortality, cardiovascular mortality, and non-cardiovascular mortality. Relationships between post-treatment LDL-C concentrations and outcomes were evaluated using restricted cubic spline (RCS) curves based on Cox proportional hazards regression analyses. Additionally, competitive risk models were employed to explore associations between LDL-C levels and cause-specific mortality. Results Among 33,968 participants, we identified nearly linear associations of post-treatment LDL-C level with all-cause mortality and CV mortality during a median follow-up of 47 months. Notably, patients who achieved the recommended target of LDL-C (<1.4 mmol/L) were at significant lower risks of all-cause mortality (HR, 0.77; 95%CI, 0.69-0.86) and CV mortality (sHR, 0.68; 95%CI, 0.58-0.79), compared with those with LDL-C ≥ 3.4 mmol/L. This survival benefit was consistent in patients with different intensity of LDL-C reduction and other subgroup analyses. And no correlation was found between post-treatment LDL-C concentration and non-CV mortality. Conclusions Our findings supported the safety of currently recommended target of LDL-C control and the “lower is better” principle in patients with ASCVD.

show abstract

Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans)

Cited by 4 publications

References 26 publications

Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review

Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review

Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease

Post-treatment level of LDL cholesterol and all-cause mortality in patients with atherosclerotic cardiovascular disease: evidence from real-world setting

Contact Info

Product

Resources

About